Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Rhiniseng   
Auth. number : EU/2/10/109
Active substance : inactivated vaccine against atrophic rhinitis in pigs
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI09 - Immunologicals for suidae
Pharmacological subgroup: QI09A - Pig
Chemical subgroup: QI09AB - Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)
Chemical substance: QI09AB04 - bordetella + pasteurella
(See WHO ATCvet Index)
Indication: For the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with Bordetella bronchiseptica and Pasteurella multocida infections during the fattening period.

Challenge studies have demonstrated that passive immunity lasts until piglets are 6 weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.
Marketing Authorisation Holder: Laboratorios Hipra, S.A.
Avda. La Selva, 135, 17170 Amer (Girona), España
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/09/2010 Centralised - Authorisation EMEA/V/C/160 (2010)6439 of 16/09/2010
23/11/2010 Corrigendum (2010)8323 cor of 22/11/2010
10/04/2015 Centralised - Variation EMEA/V/C/160/II/4
Updated with Decision(2015)4587 of 30/06/2015
02/07/2015 Centralised - Renewal EMEA/V/C/160/R/3 (2015)4587 of 30/06/2015
11/02/2016 Centralised - Variation EMEA/V/C/160/IG/623/5
Updated with Decision(2017)4123 of 23/02/2017
27/02/2017 Centralised - Yearly update (2017)4123 of 23/02/2017
22/06/2017 Centralised - Variation EMEA/V/C/160/IA/793